Clinical trials
Nervous System Diseases clinical trials
Below are recruiting nervous system diseases clinical trials, each written for real people, not researchers. We’re tracking 264 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05699200Recruiting
Study of nerves involved in spontaneous coronary artery dissection
This study looks at how the body’s automatic “fight-or-flight” nerve system may relate to spontaneous coronary artery dissection (SCAD). If you have a SCAD history, your results may help researchers understand the condition better; if you’re a healthy control, your data are compared to SCAD patients.
Rochester, MinnesotaAges 18 years+ - NCT05706532Recruiting
Test of heart and brain control in healthy adults
This study looks at how the heart and brain control itself in otherwise healthy adults. You may be able to join if you’re an adult with normal heart rhythm and no nerve-system problems affecting control.
San Donato Milanese, MilanAges 18 years+ - NCT05681936Recruiting
Brain and spine scans after spinal cord injury or related conditions
This study uses brain and spine scans (and possibly nerve stimulation in some cases) to understand how the nervous system changes after spinal cord injury or certain spinal conditions. It may help researchers better track recovery and understand which changes are linked to symptoms like bladder problems.
ZurichAges 18 years+ - NCT05641116Recruiting
Exercise plus education program for long-lasting Lyme-related symptoms
This trial tests whether a combined program of adapted exercise and therapeutic education can improve long-lasting symptoms that are thought to be related to Lyme disease. It may help people who have symptoms for over 6 months and are not very active currently.
Clermont-FerrandAges 18 years+ - NCT05550194RecruitingPhase 4
Study of an antiviral to treat achalasia-related nerve inflammation
This trial looks at whether the antiviral medicine valacyclovir, plus Shingrix vaccine, can change disease affecting the gut’s nerve system in people with achalasia. If you’re eligible, you would complete specific swallow and pressure tests and then take the medicines for about two months.
Nashville, TennesseeAges 18–75 - NCT05474378RecruitingPhase 1
CAR T cell therapy for recurrent glioblastoma
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Palo Alto, CaliforniaAges 18 years+ - NCT05256641RecruitingPhase 1/Phase 2
Acalabrutinib maintenance after transplant or CAR T for large B-cell lymphoma
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
Los Angeles, CaliforniaAges 18–70 - NCT05026983RecruitingPhase 2
Targeted drugs for melanoma spread to the brain
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
Houston, TexasAges 18 years+ - NCT04988009Recruiting
Telemedicine care experience survey for brain tumor patients
This trial asks brain tumor patients and caregivers to share what they think about the quality of care they receive through telemedicine. Your feedback may help improve how neuro-oncology visits are done by video in the future.
Houston, TexasAges 18 years+ - NCT04906096RecruitingPhase 2
Paxalisib for repeat or resistant brain lymphoma
This Phase 2 study tests paxalisib to shrink or control primary CNS lymphoma that has come back or did not respond to prior treatment. It may help by blocking specific cell-growth signals that can drive this lymphoma.
Boston, MassachusettsAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT04684368RecruitingPhase 2
New treatment for children and young adults with a brain tumor
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Birmingham, AlabamaAges 3–29 - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT04276870RecruitingPhase 2
CD19 gene-modified cells for high-risk B-cell leukemia
This Phase 2 trial studies CD19 “redirected” cells made from your own blood to treat certain high-risk or relapsed B-cell acute lymphoblastic leukemia (B-ALL). It may help by targeting cancer cells that carry a protein called CD19.
Philadelphia, PennsylvaniaAges birth–29 years - NCT04186520RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell lymphomas
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
Milwaukee, WisconsinAges 18–80 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT02896335RecruitingPhase 2
Palbociclib and pembrolizumab for brain metastases
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Birmingham, AlabamaAges Up to 25 years - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07570212Recruiting
Personalized Brain Stimulation for Parkinson's and Similar Disorders
This study tests whether customized transcranial magnetic stimulation (a non-invasive technique that uses magnetic pulses to stimulate brain activity) can help improve symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. The treatment is tailored to each person's brain activity patterns.
Beijing, Beijing MunicipalityAges 30–80 - NCT03872102Recruiting
Brain imaging study to track Parkinson-related disease changes
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
Dallas, TexasAges Any age - NCT07178210Recruiting
Robotic surgery for lymphatic drainage in Alzheimer's disease
This study tests a new robotic-assisted surgery to improve drainage of lymph fluid in the neck, which may help slow the progression of Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have specific biomarkers.
Palo Alto, CaliforniaAges 50 years+
Hear when a new Nervous System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nervous system diseases?
- Yes. Clin2 currently lists 264 recruiting nervous system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nervous system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.